Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad ...

Psoriasis drugs dominated the TV pharma ad landscape in March, as Johnson & Johnson’s Tremfya and AbbVie’s Skyrizi secured the top two spots in iSpot.tv’s ad rankings. The two drugs rose up the list ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...

For years, managing active psoriatic arthritis (PsA) has been a race against time, with irreversible joint damage and long-term disability often the heartbreaking end-point for patients. Now, a major ...

Tremfya is the first and only fully-human, dual-acting monoclonal antibody targeting IL-23 and CD64 to be approved for the treatment of moderately to severely active ulcerative colitis. The FDA has ...

"Treatment with TREMFYA resulted in significant improvement in the chronic symptoms of ulcerative colitis, and importantly, normalization in the endoscopic appearance of the intestinal lining," said ...